Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study
- PMID: 34175612
- DOI: 10.1016/j.oraloncology.2021.105419
Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study
Abstract
Purpose: We compare clinical behaviour of East-Indians and White-Canadians with oral cavity squamous cell carcinoma (OSCC) treated at a Western institution within a uniform health care system.
Materials/methods: Newly diagnosed OSCC patients who underwent postoperative (chemo-)radiotherapy (PORT/POCRT) between 2005 and 2017 were included. Data on ethnicity and other variables were extracted from patient-questionnaires, a prospective database and supplemented by chart review. Baseline characteristics were compared between East-Indian versus White-Canadian groups. A propensity-matched (1:1 ratio) of East-Indian versus White-Canadian cohorts was generated to compare locoregional control (LRC), distant control (DC), overall survival (OS), and acute and late toxicities.
Results: A total of 53 East-Indian and 467 White-Canadian OSCC patients were identified. Compared to White-Canadians, East-Indian patients were younger, had less exposure to smoking and alcohol (p < 0.001), but more chewed betel (areca) nut /tobacco (43% vs 0.2%, p < 0.001). Buccal/retromolar-trigone/lower gingiva primaries were more common in East-Indians (49% vs 25%, p < 0.001). Median follow-up was 5.0 years. Propensity-score paired analysis revealed inferior 3-year LRC (68% vs 81%, p = 0.030), non-significantly lower OS (61% vs 75%, p = 0.257), but similar DC (81% vs 87%, p = 0.428) in East-Indian versus White-Canadian patients. Actuarial rate of toxicities was higher in East-Indians vs White-Canadians: acute toxicity at 6 weeks: 47% vs 30%, p = 0.012; chronic trismus at 5-years: 16% vs 2%, p = 0.013.
Conclusion: East-Indian OSCC patients have a greater betel nut/ chewable tobacco exposure compared to White-Canadians and a different distribution of OSCC sites. Propensity-matched cohort analysis showed lower LRC and higher toxicities in East-Indian OSCC patients, suggesting a complicated interaction between genetic/biological and life-style factors.
Keywords: East-Indian; Ethnicity; Oral cavity cancer; Outcomes; Post-operative radiotherapy; Toxicity.
Copyright © 2021. Published by Elsevier Ltd.
Similar articles
-
Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in South Asians: a multicentre case-control study.Eur J Cancer. 2012 Mar;48(5):655-61. doi: 10.1016/j.ejca.2011.06.008. Epub 2011 Jul 4. Eur J Cancer. 2012. PMID: 21733677
-
Oral Cavity Cancer Outcomes in Remote, Betel Nut-Endemic Pacific Islands.Ann Otol Rhinol Laryngol. 2020 Dec;129(12):1215-1220. doi: 10.1177/0003489420934846. Epub 2020 Jun 16. Ann Otol Rhinol Laryngol. 2020. PMID: 32546006
-
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study.Radiat Oncol. 2016 Mar 22;11:47. doi: 10.1186/s13014-016-0617-7. Radiat Oncol. 2016. PMID: 27000157 Free PMC article.
-
Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms.Mutagenesis. 2004 Jul;19(4):251-62. doi: 10.1093/mutage/geh036. Mutagenesis. 2004. PMID: 15215323 Review.
-
Oral mucosal lesions associated with betel quid, areca nut and tobacco chewing habits: consensus from a workshop held in Kuala Lumpur, Malaysia, November 25-27, 1996.J Oral Pathol Med. 1999 Jan;28(1):1-4. doi: 10.1111/j.1600-0714.1999.tb01985.x. J Oral Pathol Med. 1999. PMID: 9890449 Review.
Cited by
-
Association of Household Income at Diagnosis With Financial Toxicity, Health Utility, and Survival in Patients With Head and Neck Cancer.JAMA Otolaryngol Head Neck Surg. 2023 Jan 1;149(1):63-70. doi: 10.1001/jamaoto.2022.3755. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 36416855 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical